Azurity Pharmaceuticals Absorbs Slayback Pharma
September 29, 2023
Source: drugdu
165
The company expects to yield a significant number of new medicine launches from the acquisition.
Azurity Pharmaceuticals, Inc. broke the news that it has officially acquired Slayback Pharma LLC from existing investors including KKR and Everstone Capital, making it a wholly owned subsidiary. According to Azurity, the acquisition is expected to realize its purpose of serving overlooked patients, hoping to yield a significant number of new medicine launches over the coming years.
"I am delighted to announce this combination and the increased potential it brings to do more for overlooked patients," said Richard Blackburn, CEO, Azurity. "The complementary expertise of the two companies in developing innovative dose forms will result in a strong pipeline of new medicines to meet the needs of patients. We will bring the commercial expertise of Azurity to Slayback's pipeline and look forward to introducing an even wider range of dose-forms and formulations to meet a broader set of patient needs."
Copyright©2024 Ddu. All rights reserved.
Read more on
- Is the turning point of “Cosmic Pharmaceutical Factory” coming? November 2, 2024
- It is better to look at the long-term situation November 2, 2024
- Domestic TCE polyclonal antibodies are “surging” November 2, 2024
- Medici Globalization Strategy Accelerates, Overseas Business Reaches New Heights November 2, 2024
- Ensuring patients’ peace of mind through the stable operation of medical insurance institutions and enterprises – the medical insurance department is intensifying efforts to introduce incremental policies to serve and safeguard the overall development November 2, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
